NCT06456658Completed
Statin Reminders for Improving Prescribing in Primary Care
Interruptive Versus Non-Interruptive Reminders for Statin tHerApy in Primary Care (INIRSHA-PC). A Randomized Trial.
Source: ClinicalTrials.gov · Last updated 16 Dec 2025
Brief summary (registry, in English)
Statins reduce cardiovascular events and mortality, but only 30% of eligible primary care patients nationally are on statins. Clinical decision support (CDS) interventions in the electronic health record (EHR) can deliver education to providers and increase adherence to guideline recommendations via many potential forms of delivery. Interruptive alerts are an effective form of CDS but disrupt clinician workflow and increase alert fatigue in an age of clinician burnout and frustration with the EHR. Non-interruptive reminders are proposed as an alternative method of delivering CDS; however, they require active pursuit by the provider, and their effectiveness compared to interruptive alerts has not been rigorously studied. The investigators propose a randomized trial comparing the effect of interruptive vs. non-interruptive reminders displayed to clinicians to increase statin prescribing in primary care clinics.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 3332 (actual)
- First submitted
- 7 Jun 2024
- Start date
- 14 Aug 2024
- Primary completion date
- 20 Nov 2024
- Lead sponsor
- Vanderbilt University Medical Center
- NCT number
- NCT06456658
What you commit to
- Study type: Interventional
- Participants enrolled: 3332
- From 14 Aug 2024 to the primary completion date, 20 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Already on statin, ezetimibe, bempedoic acid, or PCSK9 inhibitor
Other illness
- Statin allergy or adverse effect of statin
- Statin contraindicated due to kidney disease, defined as 1) Dialysis or 2) Estimated glomerular filtration rate less than 15 ml/min/1.73m\^2
Lab values
- Last low-density lipoprotein cholesterol (LDL-C) less than 100 mg/dL
- Statin contraindicated due to liver disease, defined as 1) Decompensated liver disease, 2) AST or ALT greater than 5 times the upper limit of normal, or 3) Total bilirubin greater than 1.5 mg/dL
- Has had coronary calcium computerized tomography
Other
- Pregnant or lactating
- Palliative care
- Rhabdomyolysis
- Less than 3 months since lipid panel resulted
- Acute visit
Who the study is looking for
- Patients between the ages of 18 and 75
- Seen in primary care visit within Vanderbilt University Medical Center
- Eligible for statin therapy due to 1) Atherosclerotic cardiovascular disease (ASCVD) 10- year risk greater than or equal to 10%, 2) Type 1 or 2 diabetes and aged 40 years or older, or 3) ASCVD diagnosis
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.